Jaguar Health 在乳腺癌患者中对 crofelemer 进行的 3 期 OnTarget 试验显示，腹泻预防有显著改善。 Jaguar Health's Phase 3 OnTarget trial for crofelemer in breast cancer patients shows significant diarrhea prevention improvement.
Jaguar Health 宣布，其旨在预防与癌症治疗相关的腹泻的 crofelemer 3 期 OnTarget 试验显示，乳腺癌患者的病情有显着改善。 Jaguar Health announced that its Phase 3 OnTarget trial for crofelemer, aimed at preventing diarrhea related to cancer therapy, showed significant improvement in breast cancer patients. 287名乳腺癌患者中有近180人参加了这一试验。 The trial included nearly 180 breast cancer participants among 287 total. 研究结果已提交给肿瘤学会议供介绍,预计将在同行评审期刊上发表。 Findings have been submitted for presentation at an oncology conference and are anticipated to be published in a peer-reviewed journal. Crofelemer 来源于热带雨林植物，可治疗胃肠道问题。 Crofelemer is derived from rainforest plants and treats gastrointestinal issues.